Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis

Abstract Activation of antigen-specific T-lymphocyte responses may be needed to cure disorders caused by chronic infection with low-risk human papillomavirus (lrHPV). Safe and effective adjuvant therapies for such disorders are needed. The safety and efficacy of a novel gorilla adenovirus vaccine ex...

Full description

Bibliographic Details
Main Authors: Maxwell Y. Lee, Simon Metenou, Douglas E. Brough, Helen Sabzevari, Ke Bai, Caroline Jochems, Jeffrey Schlom, Clint T. Allen
Format: Article
Language:English
Published: Nature Portfolio 2021-06-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-021-00348-x